Kiniksa Pharmaceuticals, Ltd.

KNSANASDAQHealthcare● Active

$49.04

+$0.62(+1.28%)

Market Cap$3.7B

P/E Ratio—

52W High$59.87

52W Low$26.27

Avg Volume693K

Open$48.80

Beta0.12

Overview

Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · KNSA · as of Jun 8, 2026

Key Statistics

EPS (TTM)$0.98Earnings history

PE Ratio (TTM)50.0×PE Ratio deep dive

Revenue (TTM)$754.0MFull revenue history

Dividend YieldNo DividendDividend history

Shares Outstanding74.2MShares outstanding history

Next EarningsJul 28, 2026Est.Earnings history

Explore Kiniksa Pharmaceuticals, Ltd. Data

Market Cap$3.7B

Analyst Forecast$64 · Buy

DividendsNo Dividend

Revenue$677.6M+60.09%

EarningsEPS $0.80+233.33%

PE Ratio50.0×

Financial Snapshot

Full Financials

FY 2025Revenue$677.6M▲ +60.09% YoY

202320242025

FY 2025Net Income$59.0M▲ +236.61% YoY

202320242025

FY 2025EPS$0.80▲ +233.33% YoY

202320242025

TTM:Revenue: $754.0MNet Income: $73.1MEPS: $0.98View income statement →

Analyst Ratings & Price Target

Full Forecast

Buy11 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

12-Month Price Target

$59.00Low

$49.04Current

$64.00Avg Target30.51% upside

$71.00High

Total: 11 · Buy rate: 100.0%

The KNSA analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $64.00, representing +30.51% upside from the current price of $49.04.

Competitors & Peers

#TickerCompanyPriceChangeMkt Cap

KNSA

Kiniksa Pharmaceuticals, Ltd.

$49.04+1.28%$3.7B #2

ADPT

Adaptive Biotechnologies Corporation

$16.79-1.18%$2.7B #3

APLS

Apellis Pharmaceuticals, Inc.

$41.03+0.00%$5.3B #4

CDTX

Cidara Therapeutics, Inc.

$221.38+0.00%$5.6B #5

CPRX

Catalyst Pharmaceuticals, Inc.

$31.28+0.03%$3.8B #6

FOLD

Amicus Therapeutics, Inc.

$14.49+0.00%$4.5B

Stock Performance

Full History

1D+0.34%

1W+2.48%

1M-17.09%

3M+5.25%

YTD+17.78%

1Y+60.19%

5Y+242.39%

About Kiniksa Pharmaceuticals, Ltd.

CEOSanj K. Patel

IPO DateMay 25, 2018

Employees315

CountryUS

Websitekiniksa.com

Kiniksa Pharmaceuticals, Ltd. is a global biopharmaceutical firm dedicated to discovering, acquiring, advancing, and commercializing medical therapies for individuals suffering from severe illnesses w…

Biotechnology HealthcareNASDAQUS

About Stock Overview & Key Data

Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 25, 2018. As of the latest trading session, KNSA stock price is $49.04, with a market capitalization of $3.7B. The stock has returned +60.19% over the past 12 months and +17.78% year-to-date.

According to 11 Wall Street analysts, the consensus rating for Kiniksa Pharmaceuticals, Ltd. stock is Buy, with an average 12-month price target of $64.00. In fiscal year 2025, Kiniksa Pharmaceuticals, Ltd. reported revenue of $677.6M and net income of $59.0M. For detailed data — including Kiniksa Pharmaceuticals, Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Kiniksa Pharmaceuticals, Ltd. (KNSA) stock price is $49.04. The stock is traded on NASDAQ under the ticker symbol KNSA. The 52-week range is $26.27 – $59.87.

KNSA stock priceKNSA quote todaylive ticker

Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice